Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016220220> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2016220220 endingPage "2609" @default.
- W2016220220 startingPage "2602" @default.
- W2016220220 abstract "Abstract BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. METHODS Forty‐one patients were treated with gemcitabine 600 mg/m 2 on Days 1, 8, and 15 and continuous‐infusion 5‐FU on Days 1–21. The dose of 5‐FU was 200 mg/m 2 per day for the initial 8 patients but was reduced to 150 mg/m 2 per day for all remaining patients due to toxicity. Starting on Day 15, IL2 and IFNA were administered for 4 weeks. IL2 was administered at a dose of 11 × 10 6 IU subcutaneously (sc) 4 days per week and IFNA was administered at a dose of 10.0 × 10 6 IU sc 2 days per week. RESULTS Of 41 patients enrolled in the study, there was 1 complete response (CR), and there were 5 partial responses (PR), for an overall response rate of 14.6% (90% confidence interval [90%CI], 6.6–26.9%). The median time to disease progression was 6.6 months (90%CI, 3.9–7.5 months), and the median overall survival was 20.6 months (90%CI, 9.6–23.3 months). Toxicity was moderate to severe, with fatigue, fever, anorexia, or nausea experienced by 75–90% of patients. Mucositis and neutropenia, likely due to the gemcitabine and 5‐FU, were experienced by a majority of patients. CONCLUSIONS The addition of gemcitabine and 5‐FU to subcutaneous IL2 and IFNA results in a similar response rate to what was observed in previous studies of IL2‐based therapy. The toxicity of this four‐drug combination is significant, and the regimen is not recommended for further development. Cancer 2002;94:2602–9. © 2002 American Cancer Society. DOI 10.1002/cncr.10528" @default.
- W2016220220 created "2016-06-24" @default.
- W2016220220 creator A5042631007 @default.
- W2016220220 creator A5059219836 @default.
- W2016220220 creator A5088131964 @default.
- W2016220220 date "2002-05-14" @default.
- W2016220220 modified "2023-10-18" @default.
- W2016220220 title "A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-? in patients with metastatic renal cell carcinoma" @default.
- W2016220220 cites W1599508346 @default.
- W2016220220 cites W1942932003 @default.
- W2016220220 cites W1945613220 @default.
- W2016220220 cites W1966497667 @default.
- W2016220220 cites W1967884480 @default.
- W2016220220 cites W1988828691 @default.
- W2016220220 cites W1995738835 @default.
- W2016220220 cites W2015605210 @default.
- W2016220220 cites W2026652010 @default.
- W2016220220 cites W2029409133 @default.
- W2016220220 cites W2066030437 @default.
- W2016220220 cites W2106428332 @default.
- W2016220220 cites W2224128977 @default.
- W2016220220 cites W2231346794 @default.
- W2016220220 cites W2270408419 @default.
- W2016220220 cites W2330814896 @default.
- W2016220220 cites W2334694951 @default.
- W2016220220 cites W4301452248 @default.
- W2016220220 cites W4366065881 @default.
- W2016220220 doi "https://doi.org/10.1002/cncr.10528" @default.
- W2016220220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12173327" @default.
- W2016220220 hasPublicationYear "2002" @default.
- W2016220220 type Work @default.
- W2016220220 sameAs 2016220220 @default.
- W2016220220 citedByCount "31" @default.
- W2016220220 countsByYear W20162202202015 @default.
- W2016220220 countsByYear W20162202202021 @default.
- W2016220220 countsByYear W20162202202022 @default.
- W2016220220 crossrefType "journal-article" @default.
- W2016220220 hasAuthorship W2016220220A5042631007 @default.
- W2016220220 hasAuthorship W2016220220A5059219836 @default.
- W2016220220 hasAuthorship W2016220220A5088131964 @default.
- W2016220220 hasBestOaLocation W20162202201 @default.
- W2016220220 hasConcept C126322002 @default.
- W2016220220 hasConcept C141071460 @default.
- W2016220220 hasConcept C2776694085 @default.
- W2016220220 hasConcept C2777063308 @default.
- W2016220220 hasConcept C2777472916 @default.
- W2016220220 hasConcept C2778397455 @default.
- W2016220220 hasConcept C2778496288 @default.
- W2016220220 hasConcept C2780258809 @default.
- W2016220220 hasConcept C2780456651 @default.
- W2016220220 hasConcept C2780580376 @default.
- W2016220220 hasConcept C29730261 @default.
- W2016220220 hasConcept C31760486 @default.
- W2016220220 hasConcept C71924100 @default.
- W2016220220 hasConcept C90924648 @default.
- W2016220220 hasConceptScore W2016220220C126322002 @default.
- W2016220220 hasConceptScore W2016220220C141071460 @default.
- W2016220220 hasConceptScore W2016220220C2776694085 @default.
- W2016220220 hasConceptScore W2016220220C2777063308 @default.
- W2016220220 hasConceptScore W2016220220C2777472916 @default.
- W2016220220 hasConceptScore W2016220220C2778397455 @default.
- W2016220220 hasConceptScore W2016220220C2778496288 @default.
- W2016220220 hasConceptScore W2016220220C2780258809 @default.
- W2016220220 hasConceptScore W2016220220C2780456651 @default.
- W2016220220 hasConceptScore W2016220220C2780580376 @default.
- W2016220220 hasConceptScore W2016220220C29730261 @default.
- W2016220220 hasConceptScore W2016220220C31760486 @default.
- W2016220220 hasConceptScore W2016220220C71924100 @default.
- W2016220220 hasConceptScore W2016220220C90924648 @default.
- W2016220220 hasIssue "10" @default.
- W2016220220 hasLocation W20162202201 @default.
- W2016220220 hasLocation W20162202202 @default.
- W2016220220 hasOpenAccess W2016220220 @default.
- W2016220220 hasPrimaryLocation W20162202201 @default.
- W2016220220 hasRelatedWork W122076965 @default.
- W2016220220 hasRelatedWork W1604979917 @default.
- W2016220220 hasRelatedWork W1979357362 @default.
- W2016220220 hasRelatedWork W1980117151 @default.
- W2016220220 hasRelatedWork W1991292752 @default.
- W2016220220 hasRelatedWork W2077610667 @default.
- W2016220220 hasRelatedWork W2086403032 @default.
- W2016220220 hasRelatedWork W2098840563 @default.
- W2016220220 hasRelatedWork W2919933703 @default.
- W2016220220 hasRelatedWork W4312195030 @default.
- W2016220220 hasVolume "94" @default.
- W2016220220 isParatext "false" @default.
- W2016220220 isRetracted "false" @default.
- W2016220220 magId "2016220220" @default.
- W2016220220 workType "article" @default.